Computational design is replacing empirical screening in drug and vaccine development.
Sovereign regulatory agencies are establishing formal qualification pathways and clinical trials to validate AI-designed vaccine antigens and in silico toxicity prediction models.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The rulemaking gives organ-on-chip, human-cell and computational substitutes formal regulatory standing in place of empirical animal screening.
The FDA's acceptance of an AI-driven digital liver model under the ISTAND program establishes a formal pathway to replace empirical animal testing with predictive computational designs.
A Phase I clinical trial successfully demonstrated the feasibility of using AI-designed synthetic super-antigens to replace empirical strain-specific targeting.
The clinical success of an entirely AI-designed super-antigen marks the transition from empirical strain screening to computational vaccine modeling.